Eli Lilly's trillion-dollar valuation, driven by off-label use of its GLP-1 drugs for weight loss, has awakened the pharmaceutical industry to the massive, previously overlooked financial opportunity in consumer-driven, non-critical medical enhancements.
Investor Christian Angermayer reframes GLP-1 use not for clinical obesity but as a tool to counteract the urge to stress-eat. This shifts the drug's purpose from a medical treatment to a performance enhancer for maintaining discipline during intense work periods.
Off-label drug use for self-improvement should always involve a doctor. This libertarian view argues supervision is not about restricting freedom, but ensuring an informed choice, because "freedom without knowledge is not real freedom. It's stupidity."
Citing research from neuroscientist David Nutt, Christian Angermayer highlights that when all harm factors are quantified—toxicity, addiction, societal damage—alcohol ranks as the most destructive recreational drug, challenging deeply ingrained social perceptions.
Glorifying sleep deprivation in high-performance careers is a liability. Working on a major deal after an all-nighter is equivalent to having a heavily intoxicated person handle it, as it severely impairs cognitive function and decision-making.
The widely cited study suggesting moderate red wine drinkers live longer has been debunked. The actual driver of longevity was not the wine itself but the strong social connections of people who tend to drink moderately with friends.
The strategy is to acquire biotech companies at valuations justified by a narrow clinical indication (e.g., premature ejaculation). The massive return comes from the "free option" of the much larger off-label consumer market (e.g., all men wanting to last longer) that is not priced in.
Investors value psychedelic companies based on the small market for treatment-resistant depression. This ignores the massive upside potential of these drugs becoming first-line treatments or even preventative tools for general mental wellness, creating a significant valuation disconnect.
The biotech industry is uniquely conservative, with a culture where even the smartest minds are beholden to established processes. This resistance to questioning norms, like automatically running two Phase 3 trials, stifles innovation and slows progress compared to other technology sectors.